Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).

Gridelli, C

Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.). [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Oct 1996 - 821-6 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

0923-7534

10.1093/oxfordjournals.annonc.a010761 doi


Adult
Aged
Antibiotics, Antineoplastic--administration & dosage
Antineoplastic Agents--administration & dosage
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Carcinoma, Non-Small-Cell Lung--drug therapy
Cisplatin--administration & dosage
Disease-Free Survival
Dose-Response Relationship, Drug
Etoposide--administration & dosage
Female
Humans
Infusions, Intravenous
Lung Neoplasms--diagnosis
Male
Middle Aged
Mitomycin--administration & dosage
Multivariate Analysis
Survival Rate
Treatment Outcome
Vindesine--administration & dosage